



Curriculum Vitae

Personal information **Eamon O Murchu**

Work experience

1. Employer: Health Products Regulatory Authority
 - Start date: 052021
 - End date:
 - Position: Medical Officer, Vigilance Assessment, Human Products Monitoring
 - Activities: Pharmacovigilance assessment, IE PRAC alternate member
 - Country: Ireland
2. Employer: Health Information and Quality Authority
 - Start date: 022018
 - End date: 052021
 - Position: Senior Health Technology Assessment Analyst
 - Activities: The assessment of the clinical effectiveness, safety, cost_effectiveness and budget impact of new technologies, including pharmaceuticals
 - Country: Ireland
3. Employer: Health Information and Quality Authority
 - Start date: 062016
 - End date: 022018
 - Position: Health Technology Assessment Analyst
 - Activities: The assessment of the clinical effectiveness, safety, cost_effectiveness and budget impact of new technologies, including pharmaceuticals
 - Country: Ireland
4. Employer: National Cancer Registry Ireland
 - Start date: 012016
 - End date: 062016
 - Position: Cancer epidemiology research
 - Activities: The evaluation of HPV_related oropharyngeal cancers in Ireland (ECHO project)
 - Country: Ireland
5. Employer: St Luke's_Roosevelt Hospital Center, New York City
 - Start date: 072012
 - End date: 072014
 - Position: Anesthesiology Residency Program
 - Activities: Resident in Anesthesiology
 - Country: United States
6. Employer: Saint Vincent Hospital, Massachusetts
 - Start date: 072011
 - End date: 072012
 - Position: Internal Medicine Program
 - Activities: Resident in Internal Medicine
 - Country: United States
7. Employer: James Connolly Memorial Hospital
 - Start date: 072009
 - End date: 072010
 - Position: Medicine and Surgery Internship
 - Activities: Medical and surgical intern
 - Country: Ireland

Education and training

1. Subject: Trinity College Dublin
 - Start date: 092016
 - End date: 052020
 - Qualification: PhD in Population Health and Health Services Research
 - Organisation: PhD title: Clinical and cost_effectiveness of a Pre_Exposure Prophylaxis (PrEP) programme to prevent HIV
 - Country: Ireland
2. Subject: University College Dublin
 - Start date: 092014
 - End date: 122015
 - Qualification: Master of Public Health _ MPH (First Class Honours)
 - Organisation:
 - Country: Ireland
3. Subject: Royal College of Surgeons in Ireland
 - Start date: 102004
 - End date: 052009
 - Qualification: Medicine _ MB BCh BAO (2:1 Honours)
 - Organisation: All core subjects in medicine, including external clinical clerkships at Cedars_Sinai Medical Center, Memorial Sloan_Kettering Cancer Center and Weill_Cornell Medical Center.
 - Country: Ireland

Additional information

Publications

1. [Oral pre-exposure prophylaxis \(PrEP\) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations.](#)
O Murchu E, Marshall L, Teljeur C, Harrington P, Hayes C, Moran P, Ryan M.
BMJ Open. 2022 May 11;12(5):e048478. doi: 10.1136/bmjopen-2020-048478.
PMID: 35545381
2. [Comparative genomic analysis demonstrates that true reinfection following SARS-CoV-2 infection is possible.](#)
O Murchu E, O'Neill S, Byrne P, De Gascun C, O'Neill M, Ryan M, Harrington P.
J Clin Virol Plus. 2021 Jun;1(1):100015. doi: 10.1016/j.jcvp.2021.100015. Epub 2021 May 4.
PMID: 35262003
3. [Systematic review of the efficacy, effectiveness and safety of MF59® adjuvanted seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age.](#)
O Murchu E, Comber L, Jordan K, Hawkshaw S, Marshall L, O'Neill M, Ryan M, Teljeur C, Carnahan A, Pérez JJ, Robertson AH, Johansen K, Jonge J, Krause T, Nicolay N, Nohynek H, Pavlopoulou I, Pebody R, Penttinen P, Soler-Soneira M, Wichmann O, Harrington P.
Rev Med Virol. 2023 May;33(3):e2329. doi: 10.1002/rmv.2329. Epub 2022 Feb 10.
PMID: 35142401
4. [Systematic review of the efficacy, effectiveness and safety of recombinant haemagglutinin seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age.](#)
O Murchu E, Comber L, Jordan K, Hawkshaw S, Marshall L, O'Neill M, Ryan M, Teljeur C, Carnahan A, Pérez JJ, Robertson AH, Johansen K, Jonge J, Krause T, Nicolay N, Nohynek H, Pavlopoulou I, Pebody R, Penttinen P, Soler-Soneira M, Wichmann O, Harrington P.
Rev Med Virol. 2023 May;33(3):e2331. doi: 10.1002/rmv.2331. Epub 2022 Feb 2.
PMID: 35106885 Review.
5. [Cost-Effectiveness Analysis of a National Pre-Exposure Prophylaxis \(PrEP\) Program in Ireland.](#)
O Murchu E, Teljeur C, Hayes C, Harrington P, Moran P, Ryan M.
Value Health. 2021 Jul;24(7):948-956. doi: 10.1016/j.jval.2021.02.005. Epub 2021 Apr 15.
PMID: 34243838
6. [Interventions in an Ambulatory Setting to Prevent Progression to Severe Disease in Patients With COVID-19: A Systematic Review.](#)
O Murchu E, Spillane S, Byrne P, O'Neill M, Harrington P, Ryan M.
Ann Pharmacother. 2022 Mar;56(3):309-318. doi: 10.1177/10600280211028242. Epub 2021 Jun 22.
PMID: 34157890
7. [Quantifying the risk of SARS-CoV-2 reinfection over time.](#)
O Murchu E, Byrne P, Carty PG, De Gascun C, Keogan M, O'Neill M, Harrington P, Ryan M.
Rev Med Virol. 2022 Jan;32(1):e2260. doi: 10.1002/rmv.2260. Epub 2021 May 27.
PMID: 34043841
8. [Immune response following infection with SARS-CoV-2 and other coronaviruses: A rapid review.](#)
O Murchu E, Byrne P, Walsh KA, Carty PG, Connolly M, De Gascun C, Jordan K, Keoghan M, O'Brien KK, O'Neill M, Smith SM, Teljeur C, Ryan M, Harrington P.
Rev Med Virol. 2021 Mar;31(2):e2162. doi: 10.1002/rmv.2162. Epub 2020 Sep 23.
PMID: 32964627
12. [Systematic review of the efficacy, effectiveness and safety of high-dose seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age.](#)
Comber L, O Murchu E, Jordan K, Hawkshaw S, Marshall L, O'Neill M, Teljeur C, Ryan M, Carnahan A, Pérez Martín JJ, Robertson AH, Johansen K, de Jonge J, Krause T, Nicolay N, Nohynek H, Pavlopoulou I, Pebody R, Penttinen P, Soler-Soneira M, Wichmann O, Harrington P.
Rev Med Virol. 2023 May;33(3):e2330. doi: 10.1002/rmv.2330. Epub 2022 Feb 4.
PMID: 35119149 Review.
13. [Airborne transmission of SARS-CoV-2 via aerosols.](#)

Comber L, O Murchu E, Drummond L, Carty PG, Walsh KA, De Gascun CF, Connolly MA, Smith SM, O'Neill M, Ryan M, Harrington P.

Rev Med Virol. 2021 May;31(3):e2184. doi: 10.1002/rmv.2184. Epub 2020 Oct 26.

PMID: 33105071

14. [Using preprints in evidence synthesis: Commentary on experience during the COVID-19 pandemic.](#)

Clyne B, Walsh KA, O'Murchu E, Sharp MK, Comber L, O' Brien KK, Smith SM, Harrington P, O'Neill M, Teljeur C, Ryan M.

J Clin Epidemiol. 2021 Oct;138:203-210. doi: 10.1016/j.jclinepi.2021.05.010. Epub 2021 May 19.

PMID: 34022394

15. [Pharmacological interventions to prevent Covid-19 disease: A rapid review.](#)

Cardwell K, O Murchu E, Byrne P, Broderick N, Walsh KA, O'Neill SM, Smith SM, Harrington P, Ryan M, O'Neill M.

Rev Med Virol. 2022 May;32(3):e2299. doi: 10.1002/rmv.2299. Epub 2021 Sep 28.

PMID: 34582072.

Projects

1. Health Research Board (HRB) Collaboration in Ireland for Clinical Effectiveness Reviews (CICER) 2. CERVIVA _ Irish Cervical Screening Research Consortium

Memberships

1. United States Medical Licensure Examinations: USMLE Step 1: 99th percentile; Step 2: 99th percentile; Step 3: 99th percentile. 2. Shani Rushin Prize for Academic Excellence 2017 (highest scoring 1st year PhD scholar). 3. Scholarship from Royal College of Surgeons Ireland (2004 – 2009). 4. Scholarship from Department of Education & Science (2004 – 2009): joint highest Leaving Certificate score in Ireland in 2004.

Other Relevant Information

Fluency in Irish language.